Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Carbenoxolone→

Carbenoxolone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
5697-56-3
Molecular formula
C34H50O7
Molecular weight
570.8 g/mol
Drug class
Licorice-derived triterpenoidanti-ulcer agent and 11β-hydroxysteroid dehydrogenase inhibitor
Mechanism of action
A glycyrrhetinic-acid derivative that inhibits 11β-hydroxysteroid dehydrogenase, reducing conversion of cortisol to cortisone in mineralocorticoid-sensitive tissues. Its gastroprotective actions have been attributed to increased mucosal resistance and effects on mucus secretion; the mechanism is not fully defined.
Indications / reported uses
  • Historically used for gastric and other digestive-tract ulcers in some countries; availability and authorised status are limited, and use can cause sodium retention, hypertension and hypokalaemia

Sources: NLM MeSH — Carbenoxolone · IUPHAR/BPS Guide to Pharmacology — Carbenoxolone · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Carbenoxolone Environmental Risk Assessment (ERA) (the Carbenoxolone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.